

Basingstoke, Southampton and Winchester

District Prescribing Committee (DPC)

Recommendations of the meeting of Tuesday 10 April 2018

Supported or limited support e.g. Specialist recommendation

- **Pentosan Polysulfate Sodium (Elmiron) caps** – these are supported for use in patients with bladder pain syndrome/interstitial cystitis. They are unlicensed in the UK and should not be prescribed in primary care. Pentosan polysulfate sodium should be classed as Red on formularies.

Not supported

- **Tadalafil** – for erectile dysfunction post nerve-sparing radical prostatectomy – based on the evidence for efficacy, safety and cost effectiveness the Committee does not support the use of tadalafil 20mg three times a week for post nerve-sparing radical prostatectomy. The committee would like to reiterate that sildenafil is the first-line PDE5 inhibitor for erectile dysfunction, Tadalafil 'on demand' is second line, if sildenafil is not tolerated/effective, or a longer duration of action required. Once daily tadalafil is non-formulary.

Other Information and formulary updates

- **Glucodrate withdrawn from market** - Glucodrate is a food for special medical purposes for use in the dietary management of short bowel-associated intestinal failure and intestinal insufficiency in adults. The manufacturer has received several reports where patients taking Glucodrate subsequently developed disordered blood biochemistry. The manufacturer is not confident that all patients taking the product in the community are being adequately monitored and have expert hospital supervision available, as recommended by ACBS for prescription of borderline substances. As patient safety cannot be guaranteed, the manufacturer has proactively decided to withdraw Glucodrate from the market, effective from Monday 5th February 2018.
- **Esmya (ulipristal acetate) temporary safety measures** - Esmya was authorised in the UK in 2012 for intermittent or pre-operative treatment of moderate to severe symptoms of uterine fibroids in women of reproductive age. Five reports of serious liver injury, including four cases of hepatic failure needing liver transplantation, have been reported worldwide. See link for the temporary safety measures have been introduced while an EU-wide review of the evidence is ongoing: <https://www.rcog.org.uk/en/guidelines-research-services/guidelines/esmya-ulipristal-acetate---mhra-safety-alert/>
- **Antibiotic guidelines**- The primary care antibiotic guidelines have now been updated and are available at the following link www.nhsantibioticguidelines.org.uk
The APP is not being updated; it will be superseded by an E-book in due course. **Please delete the APP from mobile devices**
- **Responsibility for prescribing between primary and secondary/tertiary care** - This NHS framework was noted and accepted by the committee members who agreed that the principles would be used as a template for future development of shared care arrangements
- **Southern Health update** – Clozapine guidelines have been updated, All patients on Modecate (fluphenazine decanoate) injection will be reviewed before the product is discontinued later this year
- **Aspirin in pregnancy**- A template letter for GPs (from UHS) requesting aspirin prescribing in pregnancy for specific indications was endorsed by the committee

➤ Guidance documents are available [Here](#) (hosted by West Hampshire CCG)

Summarised on behalf of the District Prescribing Committee by Andrea White (Southampton City CCG)